Systemic therapy of metastatic bladder cancer in the molecular era: current status and future promise

Dasatinib Is Preclinically Active against Src-Overexpressing Human Transitional Cell Carcinoma of the Urothelium with Activated Src Signaling

(2010) J. M. Levitt et al.   MOLECULAR CANCER THERAPEUTICS

A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102

(2009) G. K. Philips et al.   ANNALS OF ONCOLOGY

Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner

(2009) Thomas W. Flaig et al.   BJU INTERNATIONAL

Cancer Statistics, 2009

(2009) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Phase 2 trial of sorafenib in patients with advanced urothelial cancer

(2009) Robert Dreicer et al.   CANCER

A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma

(2009) Christian Wülfing et al.   CANCER

Phase I Trial of Pazopanib in Patients with Advanced Cancer

(2009) H. I. Hurwitz et al.   CLINICAL CANCER RESEARCH

Second-line therapy in bladder cancer

(2009) Mark Bachner et al.   CURRENT OPINION IN UROLOGY

Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors

(2009) Quincy Siu-Chung Chu   EXPERT OPINION ON BIOLOGICAL THERAPY

Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract

(2009) Joaquim Bellmunt et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment of metastatic urothelial cancer: opportunities for drug discovery and development

(2008) Guru Sonpavde et al.   BJU INTERNATIONAL

Advanced bladder cancer: Status of first-line chemotherapy and the search for active agents in the second-line setting

(2008) David J. Gallagher et al.   CANCER

Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases

(2008) P MEDINA et al.   CLINICAL THERAPEUTICS

Src and focal adhesion kinase as therapeutic targets in cancer

(2008) Valerie G Brunton et al.   CURRENT OPINION IN PHARMACOLOGY

Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy

(2008) Karl S. Peggs et al.   IMMUNOLOGICAL REVIEWS

Quantitation of Aurora Kinase A Gene Copy Number in Urine Sediments and Bladder Cancer Detection

(2008) Hong-Seok Park et al.   JNCI-Journal of the National Cancer Institute

Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model

(2008) Guru Sonpavde et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Epidermal growth factor receptor expression: predictive value for the outcome after cystectomy for bladder cancer?

(2003) Sriplakich et al.   BJU INTERNATIONAL